This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
"At a time when most Americans are demanding long overdue changes in federal cannabis policy, Acting DEA Administrator Derek Maltz epitomizes the failed policies and approaches of the past. The post Career Drug Warrior Named Acting DEA Administrator appeared first on NORML.
"At a time when voters and their elected officials nationwide are re-evaluating state and federal marijuana policies, it is inconceivable that government agencies are unwilling to provide data on the estimated costs and scope of federal marijuana prohibition in America."
According to figures published in the DEA’s Domestic Cannabis Eradication/Suppression Statistical Report , the agency and its law enforcement partners confiscated an estimated four million marijuana plants in 2019 – up from 2.8 It was the second-lowest number of arrests reported by the DEA in the past decade.
NORML's Deputy Director Paul Armentano said that he was disappointed but hardly surprised by the DEA's decision to disproportionately include groups opposed to marijuana policy reform as designated participants.
DEA Potential Reclassification of Marijuana Policy. In recent discussions surrounding drug policy reform, the reclassification of marijuana by the Drug Enforcement Administration (DEA) has emerged as a pivotal issue. Read More
A federal court has ordered the Drug Enforcement Administration to respond to a lawsuit charging the agency with failing to move forward with a 2016 policy to expand the total number of federally licensed marijuana cultivators. “[This filing is] asking the court for an order compelling the DEA to process our application.
As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. In 2016, the agency appeared to reconsider its longstanding policy, and publicly stated for the first time that it would consider additional applicants.
The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.
Members of the House Energy and Commerce Subcommittee on Health today held a legislative hearing, “ Cannabis Policies for the New Decade ,” during which they considered multiple legislative bills aimed at amending federal cannabis laws. He continued: “The fact of the matter is that legalization and regulation work.
Biden's attorney general, DEA head, and 'drug czar' will carry out his drug policies. Drug policy leaders offer plenty of options appeared first on Leafly. Who should get the jobs? The post Who should Biden appoint?
The DEA now estimates that, under the new rules, it may approve between three and 15 total applicants. ” He added, “Further, the DEA has an incredibly poor track record in this arena – having for years now promised to expedite and streamline this process, but failing to deliver.
On October 15, 2017, the Washington Post and 60 Minutes released a scathing report on the pharmaceutical industry’s influence of the Drug Enforcement Administration (DEA).
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
In August 2016, the US Drug Enforcement Administration announced in the US Federal Register that the agency was “adopting a new policy that is designed to increase the number of entities registered under the Controlled Substances Act to grow (manufacture) marijuana to supply legitimate researchers in the United States.”
All that is about to change, thanks to a change at the DEA , which cultivators and industry experts say will be monumental for cannabis research, medical marijuana patients, and potentially the broader legal status of the plant itself. “We Unfortunately, this change in policy has been promised for years and never actually materialized.”.
Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.
Lawyers for the group appealed that decision, asking the court to order DEA to initiate a formal rulemaking process, which would involve expert testimony and public comment. Court Dismisses DEA Marijuana Rescheduling Case, But Judge Says Cannabis Reclassification May Be Coming Anyway. In a ruling filed on Monday, the U.S.
Sixty-three percent of respondents also agreed, “The DEA should reclassify marijuana so that it is no longer a schedule I drug.". Of eligible respondents, 72 percent agreed with the statement, “Medical marijuana should be used to reduce the use of opioids for non-cancer pain.”
Drug Enforcement Administration (DEA) when it comes to DEA’s handling of petitions to remove marijuana from the list of most dangerous drugs. Since then many different parties have tried to reschedule or end prohibition by filing petitions with DEA per the CSA protocol on rescheduling.
Perhaps most tellingly, our political opponents are also touting its significance, pledging to take whatever steps necessary to derail this proposed policy change. The post Federal Marijuana Rescheduling Announced appeared first on NORML.
Some states have regulated Hemp CBD despite the FDA’s slow movement, others are locked into the FDA’s policy, banning Hemp CBD in foods and dietary supplements. A positive statement like this from Dr. Hahn, made directly to the NASDA is likely to have ripple effects on enforcement policies across the state. Conclusion.
As the result of a lawsuit, DEA Administrative Law Judge Mary Ellen Bittner in 2007 ruled that expanding the pool of federally licensed providers would be “in the public interest.” The agency ultimately rejected her decision.
Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”
This Wednesday, January 15th, at 10 am EST, the House Energy and Commerce Subcommittee on Health will hold a legislative hearing entitled “Cannabis Policies for the New Decade.” ” This marks the first time that members of the Energy and Commerce Committee will hear and debate issues specific to marijuana policy reform.
Indeed, the DEA reports that it is “aggressively striving to halt the spread of cannabis cultivation in the United States,” including through its Domestic Cannabis Eradication/Suppression Program (DCE/SP), which began funding eradication programs in 1979 and has approximately 126 state and local law enforcement agency participants.
Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. This likely would have been longer, but the DEA had not anticipated a legal threat to force some action. Given the DEA’s stonewalling, forcing their hand is a notable achievement. Dozens of Applications”. .
August 24, 2020 The DEA has not issued a warning or otherwise signaled a change in enforcement policy by issuing the interim final rule. The post Duane Morris Article: DEA Issues Interim Final Rule Concerning Marijuana and Hemp first appeared on Cannabis Law Report. On … Read More.
Reuters Reports have surfaced indicating that the Biden administration is gearing up to shake up federal drug policy. Drug Enforcement Administration (DEA) is reportedly considering reclassifying marijuana, a move that could mark a significant shift in decades-long restrictions. According to NBC News, the DEA is set to greenlight.
At least five federal agencies currently have juristiction when it comes to cannabis policy; The DOJ, the DEA, the FDA, the Office of National Drug Control Policy, and, the Department of Health and Human Services. What is going to happen when cannabis policy changes occur at the federal level?
The annual DEA report also shows that federal law enforcement officers made nearly 5,000 cannabis-related arrests in 2020, a year wracked by the social and economic fallout of the Covid-19 pandemic. Nationwide, agents seized more than $41 million in assets related to the DEA’s marijuana eradication efforts in 2020.
The recommendation by the FDA and HHS to reclassify marijuana as a Schedule III substance marks a pivotal shift in federal drug policy, acknowledging its medical benefits and potential for lower abuse.
On November 16, 2021, the Drug Enforcement Agency (DEA) issued an advance notice of proposed rulemaking , exploring whether or not to create new federal regulations governing the practice of telepharmacy. The DEA’s notice provides the industry with an opportunity to provide insight and feedback that may help shape the new regulations.
Drug Enforcement Agency (DEA) made far fewer cannabis-related arrests in 2019 than in previous years. Let’s take a closer look at what DEA data reveals. But despite all the DEA’s seizing and destroying, it’s clear that the average U.S. That’s what DEA data indicates, at least — especially when looked at closely.
Drug Enforcement Agency (“DEA”). Given the alarming and noticeable increase in ayahuasca border seizures in 2020, the main intent of these initial requests was to see how many seizures happened that year and if the government had a specific policy regarding these seizures. Customs Border Patrol (“CBP”) and U.S. 562 [2011]).
Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis. DEA finally relents.
The DEA’s announcement signals the “beginning of the end” of federal marijuana prohibition, as the policy change allows federal agencies to evaluate and assess the medical use and abuse potential of marijuana with (limited) political interference. BY EMILY BURNS, GREEN LIGHT LAW GROUP —.
This occasion marks the first time that a federal agency has recommended rescheduling cannabis, and this could be the push the Drug Enforcement Administration (DEA) needs to finally make it happen. The DEA holds the final authority on cannabis rescheduling, and they have yet to state whether they plan on taking this action.
We have noted previously that the federal Drug Enforcement Agency (DEA) recently announced that drugs that include CBD (cannabidiol) with less than 0.1% We had previously blogged on The Stoned Age: What the CBD Craze Means for Employers and Their Substance Abuse Policies , CBD is Everywhere – But Where Does the FDA Stand? ,
Well, the DEA just released its 2020 National Drug Threat Assessment, and the report is full of stats on the United States’ most popular illegal addictions, new trends in intoxicants, and foreign trade — a.k.a. The US sourced 92 percent of its heroin from Mexico in 2019, according to product analyzed by a DEA tracing program.
“It is significant for these federal agencies, and the DEA and FDA in particular, to acknowledge publicly for the first time what many patients and advocates have known for decades: that cannabis is a safe and effective therapeutic agent for tens of millions of Americans.”
CannaTech showcases the biggest industry thought leaders, known for their significant and groundbreaking contributions to the global cannabis market in fields such as science, finance, government policy and tech. policy towards marijuana. Where is it all headed?” Cannabis evolution under the Obama Administration.
Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.
MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs). 5 cannabis strains to treat PTSD: 1.
However, the DEA and FDA still consider CBD a drug regulated under the Schedule I classification. The DEA definition of a Schedule 1 substance is : Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content